Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D07SZJ
|
|||
Former ID |
DIB014734
|
|||
Drug Name |
A-75169
|
|||
Synonyms |
A-74324; A-74325
Click to Show/Hide
|
|||
Indication | Glaucoma/ocular hypertension [ICD-11: 9C61; ICD-9: 365] | Terminated | [1] | |
Company |
Abbott Laboratories
|
|||
Structure |
Download2D MOL |
|||
Formula |
C20H26ClNO
|
|||
Canonical SMILES |
CN(CCC1=CC=CC=C1)CC2CCCC3=C2C=CC(=C3)O.Cl
|
|||
InChI |
1S/C20H25NO.ClH/c1-21(13-12-16-6-3-2-4-7-16)15-18-9-5-8-17-14-19(22)10-11-20(17)18;/h2-4,6-7,10-11,14,18,22H,5,8-9,12-13,15H2,1H3;1H
|
|||
InChIKey |
APKIWAWHUXJRIV-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Adrenergic receptor alpha-2C (ADRA2C) | Target Info | Modulator | [2] |
KEGG Pathway | cGMP-PKG signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Panther Pathway | Alpha adrenergic receptor signaling pathway | |||
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
Reactome | Adrenoceptors | |||
Adrenaline signalling through Alpha-2 adrenergic receptor | ||||
Adrenaline,noradrenaline inhibits insulin secretion | ||||
G alpha (i) signalling events | ||||
G alpha (z) signalling events | ||||
Surfactant metabolism | ||||
WikiPathways | Monoamine GPCRs | |||
GPCRs, Class A Rhodopsin-like | ||||
Platelet Aggregation (Plug Formation) | ||||
Integration of energy metabolism | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003469) | |||
REF 2 | A-75169 HCI: Pharmacological profile and ocular pharmacology studies of a new alpha-2 antagonist. Drug Development Research Volume 28, Issue 1, pages 56-64, January 1993. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.